FDA approves new drug for canine allergic skin conditions

FDA approves new drug for canine allergic skin conditions


For the millions of dogs suffering from skin allergy conditions, there’s a new drug that may help control symptoms.

In September 2024, the US Food and Drug Administration, or FDA, approved once-daily Zenrelia [zen-REH-lee-ah] tablets for the control of itching associated with allergic dermatitis and the control of environmental allergies — also known as atopic dermatitis — in dogs at least one year of age.

Zenrelia works, in part, by suppressing the immune system. Since vaccine protection relies on a strong immune response, dogs should not be vaccinated at least 28 days before or after treatment with Zenrelia.  

As with other drugs of its class, Zenrelia is only available by prescription from a licensed veterinarian.

Related Episodes